New Research from the CWMH: No Increase in Major Malformations in Children with Prenatal Exposure to Olanzapine
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
In this population seeking treatment for PMDD, suicidal ideation is very common, affecting about 40% of the women.
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
Despite the unequivocal benefits of folic acid supplementation and recommendations urging all women of reproductive age to take folic acid supplements, preconceptual use of folic acid has not increased substantially.
Prenatal opioid use is associated with increased maternal and infant mortality, prematurity, and poor neonatal outcomes.
In a cohort of 351 children exposed to second generation antipsychotic during pregnancy, the risk of major congenital malformations did not differ from a comparison group of non-exposed children.
Prenatal exposure to antipsychotic medications was not associated with increased risk of neurodevelopmental disorders in offspring.
In this large study with over 1500 exposures, duloxetine exposure during the first trimester does not appear to increase risk of major malformations.
Lamotrigine is detected in the breast milk and in the serum of the nursing infant; however, the risk of adverse events is very low.